Eviana® is a single tablet for oral administration containing 0.5 mg of 17β-estradiol and 0.1 mg of norethindrone acetate
Eviana® is the second NN HRT generation of low dose and the only ultra low dose which is available. Compare to activelle Eviana® is containing half dose of 17β-estradiol (0.5 mg vs.1 mg) and 80% less dose of progesterone NETA (0.1 mg vs. 0.5 mg)
* The only ultra low dose combination Eviana® is consistent with the advice
of the regulatory authorities to prescribe the lowest effective dose
* Minimizing progesterone dose is an important aspect of current HRT development.
* Eviana® is the only ultra low dose in the market compare to other products
* The ultra low dose product Eviana® significantly reduced the frequency and severity of moderate to severe postmenopausal hot flushes
* Lower doses have also been shown to prevent osteoporosis
* The ultra low dose combination Eviana® has a neutral effect on the breast(Smaller increase in mammography density )
* No reports of thromboembolic events
Eviana® 
